Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study

The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients’ exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of dama...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology international 2015-07, Vol.35 (7), p.1225-1232
Hauptverfasser: Koutsonikoli, Artemis, Trachana, Maria, Heidich, Anna-Bettina, Galanopoulou, Vasiliki, Pratsidou-Gertsi, Polyxeni, Garyphallos, Alexandros
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1232
container_issue 7
container_start_page 1225
container_title Rheumatology international
container_volume 35
creator Koutsonikoli, Artemis
Trachana, Maria
Heidich, Anna-Bettina
Galanopoulou, Vasiliki
Pratsidou-Gertsi, Polyxeni
Garyphallos, Alexandros
description The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients’ exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of damage accrual in cSLE patients overtime and investigate for predisposing factors. Disease characteristics and treatment in 47 Northern Greek Caucasian cSLE patients were retrospectively reviewed. The Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) was used for damage assessment and the European Consensus Lupus Activity Measurement (ECLAM) to monitor cSLE activity. After a median disease duration of 7.4 years, 17/47 patients (36 %) had developed damage (SDI > 0). The most frequent domains damaged were the ocular (41 %), neuropsychiatric (35 %) and peripheral vascular (35 %) one. Peripheral vascular and neuropsychiatric damage was seen more frequently during the first 5 years of the disease. Longer exposure to azathioprine was associated with higher SDI at the end of follow-up ( β  = 0.008 for every additional month of use, p  = 0.041). The mean annual flare frequency was associated with a shorter time interval until the development of the first damage (hazard’s ratio, HR 2.38 for each unit of increase, p  = 0.018), while hydroxychloroquine use was associated with longer time interval (HR 0.19, p  = 0.007). The lower rates of damage accrual in this study compared to other cohorts might be due to milder disease phenotype in Greek Caucasian cSLE patients, prompt diagnosis and effective disease control. Damage was noticed early in the disease course, and one-third of patients had an SDI > 0 at study completion. Disease flares and a severe disease course leading to prolonged use of immunosuppressives were significant risk factors, while hydroxychloroquine use was protective against cSLE damage accrual.
doi_str_mv 10.1007/s00296-014-3209-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1682204651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1682204651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-76e83bb5d3caf0091412d6cec231c9a579acd0b0c618ccd1e73e13589bbae6673</originalsourceid><addsrcrecordid>eNp1kU-L1TAUxYMozpvRD-BGAm7cRPOnTVt3MjqjMOhGwV1Ik_teM7ZNzU2Vt_Ojm_JGEcFNQnJ_59zcHEKeCP5CcN68RM5lpxkXFVOSd0zfIztRqYYJzb_cJzsuGsnaspyRc8RbXs5a84fkTNZ1q3WtduTnm4AILof5QPMA1NvJHoCGmX6IqVykmV4ngK90sTnAnJH-CHmgbgijH2L0LM4ImeIRM0zB0XFdVqSQjkU72RxxxVfU0gQ5RVy2Rt-BujgUc4p59cdH5MHejgiP7_YL8vnq7afLd-zm4_X7y9c3zFWVzKzR0Kq-r71yds95JyohvXbgpBKus3XTWed5z50WrXNeQKNAqLrt-t6C1o26IM9PvkuK31bAbKaADsbRzhBXNEK3UvJK16Kgz_5Bb-Oa5vK6jSofXFV8o8SJcmUyTLA3SwqTTUcjuNniMad4TInHbPEYXTRP75zXfgL_R_E7jwLIE4ClNB8g_dX6v66_AJ7OnV0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1681434401</pqid></control><display><type>article</type><title>Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Koutsonikoli, Artemis ; Trachana, Maria ; Heidich, Anna-Bettina ; Galanopoulou, Vasiliki ; Pratsidou-Gertsi, Polyxeni ; Garyphallos, Alexandros</creator><creatorcontrib>Koutsonikoli, Artemis ; Trachana, Maria ; Heidich, Anna-Bettina ; Galanopoulou, Vasiliki ; Pratsidou-Gertsi, Polyxeni ; Garyphallos, Alexandros</creatorcontrib><description>The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients’ exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of damage accrual in cSLE patients overtime and investigate for predisposing factors. Disease characteristics and treatment in 47 Northern Greek Caucasian cSLE patients were retrospectively reviewed. The Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) was used for damage assessment and the European Consensus Lupus Activity Measurement (ECLAM) to monitor cSLE activity. After a median disease duration of 7.4 years, 17/47 patients (36 %) had developed damage (SDI &gt; 0). The most frequent domains damaged were the ocular (41 %), neuropsychiatric (35 %) and peripheral vascular (35 %) one. Peripheral vascular and neuropsychiatric damage was seen more frequently during the first 5 years of the disease. Longer exposure to azathioprine was associated with higher SDI at the end of follow-up ( β  = 0.008 for every additional month of use, p  = 0.041). The mean annual flare frequency was associated with a shorter time interval until the development of the first damage (hazard’s ratio, HR 2.38 for each unit of increase, p  = 0.018), while hydroxychloroquine use was associated with longer time interval (HR 0.19, p  = 0.007). The lower rates of damage accrual in this study compared to other cohorts might be due to milder disease phenotype in Greek Caucasian cSLE patients, prompt diagnosis and effective disease control. Damage was noticed early in the disease course, and one-third of patients had an SDI &gt; 0 at study completion. Disease flares and a severe disease course leading to prolonged use of immunosuppressives were significant risk factors, while hydroxychloroquine use was protective against cSLE damage accrual.</description><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-014-3209-6</identifier><identifier>PMID: 25586653</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Age of Onset ; Child ; Disease Progression ; European Continental Ancestry Group ; Female ; Greece - epidemiology ; Humans ; Immunosuppressive Agents - therapeutic use ; Longitudinal Studies ; Lupus Erythematosus, Systemic - diagnosis ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - ethnology ; Male ; Medicine ; Medicine &amp; Public Health ; Original Article - Observational Research ; Phenotype ; Protective Factors ; Retrospective Studies ; Rheumatology ; Risk Factors ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Rheumatology international, 2015-07, Vol.35 (7), p.1225-1232</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-76e83bb5d3caf0091412d6cec231c9a579acd0b0c618ccd1e73e13589bbae6673</citedby><cites>FETCH-LOGICAL-c442t-76e83bb5d3caf0091412d6cec231c9a579acd0b0c618ccd1e73e13589bbae6673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00296-014-3209-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00296-014-3209-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25586653$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koutsonikoli, Artemis</creatorcontrib><creatorcontrib>Trachana, Maria</creatorcontrib><creatorcontrib>Heidich, Anna-Bettina</creatorcontrib><creatorcontrib>Galanopoulou, Vasiliki</creatorcontrib><creatorcontrib>Pratsidou-Gertsi, Polyxeni</creatorcontrib><creatorcontrib>Garyphallos, Alexandros</creatorcontrib><title>Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients’ exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of damage accrual in cSLE patients overtime and investigate for predisposing factors. Disease characteristics and treatment in 47 Northern Greek Caucasian cSLE patients were retrospectively reviewed. The Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) was used for damage assessment and the European Consensus Lupus Activity Measurement (ECLAM) to monitor cSLE activity. After a median disease duration of 7.4 years, 17/47 patients (36 %) had developed damage (SDI &gt; 0). The most frequent domains damaged were the ocular (41 %), neuropsychiatric (35 %) and peripheral vascular (35 %) one. Peripheral vascular and neuropsychiatric damage was seen more frequently during the first 5 years of the disease. Longer exposure to azathioprine was associated with higher SDI at the end of follow-up ( β  = 0.008 for every additional month of use, p  = 0.041). The mean annual flare frequency was associated with a shorter time interval until the development of the first damage (hazard’s ratio, HR 2.38 for each unit of increase, p  = 0.018), while hydroxychloroquine use was associated with longer time interval (HR 0.19, p  = 0.007). The lower rates of damage accrual in this study compared to other cohorts might be due to milder disease phenotype in Greek Caucasian cSLE patients, prompt diagnosis and effective disease control. Damage was noticed early in the disease course, and one-third of patients had an SDI &gt; 0 at study completion. Disease flares and a severe disease course leading to prolonged use of immunosuppressives were significant risk factors, while hydroxychloroquine use was protective against cSLE damage accrual.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age of Onset</subject><subject>Child</subject><subject>Disease Progression</subject><subject>European Continental Ancestry Group</subject><subject>Female</subject><subject>Greece - epidemiology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Longitudinal Studies</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - ethnology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Original Article - Observational Research</subject><subject>Phenotype</subject><subject>Protective Factors</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU-L1TAUxYMozpvRD-BGAm7cRPOnTVt3MjqjMOhGwV1Ik_teM7ZNzU2Vt_Ojm_JGEcFNQnJ_59zcHEKeCP5CcN68RM5lpxkXFVOSd0zfIztRqYYJzb_cJzsuGsnaspyRc8RbXs5a84fkTNZ1q3WtduTnm4AILof5QPMA1NvJHoCGmX6IqVykmV4ngK90sTnAnJH-CHmgbgijH2L0LM4ImeIRM0zB0XFdVqSQjkU72RxxxVfU0gQ5RVy2Rt-BujgUc4p59cdH5MHejgiP7_YL8vnq7afLd-zm4_X7y9c3zFWVzKzR0Kq-r71yds95JyohvXbgpBKus3XTWed5z50WrXNeQKNAqLrt-t6C1o26IM9PvkuK31bAbKaADsbRzhBXNEK3UvJK16Kgz_5Bb-Oa5vK6jSofXFV8o8SJcmUyTLA3SwqTTUcjuNniMad4TInHbPEYXTRP75zXfgL_R_E7jwLIE4ClNB8g_dX6v66_AJ7OnV0</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Koutsonikoli, Artemis</creator><creator>Trachana, Maria</creator><creator>Heidich, Anna-Bettina</creator><creator>Galanopoulou, Vasiliki</creator><creator>Pratsidou-Gertsi, Polyxeni</creator><creator>Garyphallos, Alexandros</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20150701</creationdate><title>Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study</title><author>Koutsonikoli, Artemis ; Trachana, Maria ; Heidich, Anna-Bettina ; Galanopoulou, Vasiliki ; Pratsidou-Gertsi, Polyxeni ; Garyphallos, Alexandros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-76e83bb5d3caf0091412d6cec231c9a579acd0b0c618ccd1e73e13589bbae6673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age of Onset</topic><topic>Child</topic><topic>Disease Progression</topic><topic>European Continental Ancestry Group</topic><topic>Female</topic><topic>Greece - epidemiology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Longitudinal Studies</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - ethnology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Original Article - Observational Research</topic><topic>Phenotype</topic><topic>Protective Factors</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koutsonikoli, Artemis</creatorcontrib><creatorcontrib>Trachana, Maria</creatorcontrib><creatorcontrib>Heidich, Anna-Bettina</creatorcontrib><creatorcontrib>Galanopoulou, Vasiliki</creatorcontrib><creatorcontrib>Pratsidou-Gertsi, Polyxeni</creatorcontrib><creatorcontrib>Garyphallos, Alexandros</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koutsonikoli, Artemis</au><au>Trachana, Maria</au><au>Heidich, Anna-Bettina</au><au>Galanopoulou, Vasiliki</au><au>Pratsidou-Gertsi, Polyxeni</au><au>Garyphallos, Alexandros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>35</volume><issue>7</issue><spage>1225</spage><epage>1232</epage><pages>1225-1232</pages><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>The improved survival of childhood-onset systemic lupus erythematosus (cSLE) has resulted in longer patients’ exposure to disease inflammation, medications and/or comorbid diseases, which can all contribute to the development of organ damage. The aim of this study was to assess the evolution of damage accrual in cSLE patients overtime and investigate for predisposing factors. Disease characteristics and treatment in 47 Northern Greek Caucasian cSLE patients were retrospectively reviewed. The Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) was used for damage assessment and the European Consensus Lupus Activity Measurement (ECLAM) to monitor cSLE activity. After a median disease duration of 7.4 years, 17/47 patients (36 %) had developed damage (SDI &gt; 0). The most frequent domains damaged were the ocular (41 %), neuropsychiatric (35 %) and peripheral vascular (35 %) one. Peripheral vascular and neuropsychiatric damage was seen more frequently during the first 5 years of the disease. Longer exposure to azathioprine was associated with higher SDI at the end of follow-up ( β  = 0.008 for every additional month of use, p  = 0.041). The mean annual flare frequency was associated with a shorter time interval until the development of the first damage (hazard’s ratio, HR 2.38 for each unit of increase, p  = 0.018), while hydroxychloroquine use was associated with longer time interval (HR 0.19, p  = 0.007). The lower rates of damage accrual in this study compared to other cohorts might be due to milder disease phenotype in Greek Caucasian cSLE patients, prompt diagnosis and effective disease control. Damage was noticed early in the disease course, and one-third of patients had an SDI &gt; 0 at study completion. Disease flares and a severe disease course leading to prolonged use of immunosuppressives were significant risk factors, while hydroxychloroquine use was protective against cSLE damage accrual.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25586653</pmid><doi>10.1007/s00296-014-3209-6</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0172-8172
ispartof Rheumatology international, 2015-07, Vol.35 (7), p.1225-1232
issn 0172-8172
1437-160X
language eng
recordid cdi_proquest_miscellaneous_1682204651
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adolescent
Adult
Age of Onset
Child
Disease Progression
European Continental Ancestry Group
Female
Greece - epidemiology
Humans
Immunosuppressive Agents - therapeutic use
Longitudinal Studies
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - ethnology
Male
Medicine
Medicine & Public Health
Original Article - Observational Research
Phenotype
Protective Factors
Retrospective Studies
Rheumatology
Risk Factors
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult
title Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A58%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissecting%20the%20damage%20in%20Northern%20Greek%20patients%20with%20childhood-onset%20systemic%20lupus%20erythematosus:%20a%20retrospective%20cohort%20study&rft.jtitle=Rheumatology%20international&rft.au=Koutsonikoli,%20Artemis&rft.date=2015-07-01&rft.volume=35&rft.issue=7&rft.spage=1225&rft.epage=1232&rft.pages=1225-1232&rft.issn=0172-8172&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-014-3209-6&rft_dat=%3Cproquest_cross%3E1682204651%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1681434401&rft_id=info:pmid/25586653&rfr_iscdi=true